Pfizer BioNTech vaccine likely to be effective against B1.1.7 strain of SARS-CoV-2
Covid-19: People who have had infection might only need one dose of mRNA vaccine
2 February 2021Researchers develop 10-minute COVID-19 diagnostic test that wage workers can afford
2 February 2021Pfizer BioNTech vaccine likely to be effective against B1.1.7 strain of SARS-CoV-2
The Pfizer BioNTech vaccine BNT162b2 is likely to be effective against the B1.1.7 variant of SARS-CoV-2, even though its efficacy is modestly affected, say scientists at the University of Cambridge. However, when the E484K mutation—first seen in the South African variant—is added, it substantially increases the amount of antibody required to prevent infection.
